Loading…
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
58pct
2d open
vs 10,564 other HR bills in the 118th — cohort avg 68d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (34)
Forwarded by Subcommittee to Full Committee in the Nature of a Substitute (Amended) by the Yeas and Nays: 27 - 0 .
Subcommittee Consideration and Mark-up Session Held.
Referred to the Subcommittee on Health.
Referred to the House Committee on Energy and Commerce.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2025 · fourth_quarter · Health Issues
Sustainability of safety net health systems; social determinants of health; promoting coordinated care; support of telehealth policies; 340B Protect Act, H.R. 4390; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 3281, the Transparent PRICE Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2665, the Supporting Safety Net Hospitals Act; and H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023; H.R. 5378, the Lower Costs, More Transparency Act; S.3548, the Health Care Prices Revealed and Information to Consumers Explained Transparency Act; H.R.6363, the Further Continuing Appropriations and Other Extensions Act, 2024; H.R. 2872, Further Additional Continuing Appropriations and Other Extensions Act, 2024; H.R. 7463, Extension of Continuing Appropriations and Other Matters Act, 2024; H.R. 8574, the 340B Affording Care for Communities and Ensuring a Strong Safety-net Act; H.R. 10337, Expanding the Health Care Workforce Act; and H.R. 4392, Uterine Fibroid Intervention and Gynecological Health Treatment Act of 2025.
Client expense: $230,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2025 · fourth_quarter · Health Issues
Sustainability of safety net health systems; social determinants of health; promoting coordinated care; support of telehealth policies; 340B Protect Act, H.R. 4390; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 3281, the Transparent PRICE Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2665, the Supporting Safety Net Hospitals Act; and H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023; H.R. 5378, the Lower Costs, More Transparency Act; S.3548, the Health Care Prices Revealed and Information to Consumers Explained Transparency Act; H.R.6363, the Further Continuing Appropriations and Other Extensions Act, 2024; H.R. 2872, Further Additional Continuing Appropriations and Other Extensions Act, 2024; H.R. 7463, Extension of Continuing Appropriations and Other Matters Act, 2024; H.R. 8574, the 340B Affording Care for Communities and Ensuring a Strong Safety-net Act; H.R. 10337, Expanding the Health Care Workforce Act; and H.R. 4392, Uterine Fibroid Intervention and Gynecological Health Treatment Act of 2025.
Client expense: $150,000 · Firm income: Not reported
2025 · third_quarter · Health Issues
Sustainability of safety net health systems; social determinants of health; promoting coordinated care; support of telehealth policies; 340B Protect Act, H.R. 4390; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 3281, the Transparent PRICE Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2665, the Supporting Safety Net Hospitals Act; and H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023; H.R. 5378, the Lower Costs, More Transparency Act; S.3548, the Health Care Prices Revealed and Information to Consumers Explained Transparency Act; H.R.6363, the Further Continuing Appropriations and Other Extensions Act, 2024; H.R. 2872, Further Additional Continuing Appropriations and Other Extensions Act, 2024; H.R. 7463, Extension of Continuing Appropriations and Other Matters Act, 2024; H.R. 8574, the 340B Affording Care for Communities and Ensuring a Strong Safety-net Act; H.R. 10337, Expanding the Health Care Workforce Act; and H.R. 4392, Uterine Fibroid Intervention and Gynecological Health Treatment Act of 2025.
Client expense: $150,000 · Firm income: Not reported
2025 · second_quarter · Health Issues
Sustainability of safety net health systems; social determinants of health; promoting coordinated care; support of telehealth policies; 340B Protect Act, H.R. 4390; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 3281, the Transparent PRICE Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2665, the Supporting Safety Net Hospitals Act; and H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023; H.R. 5378, the Lower Costs, More Transparency Act; S.3548, the Health Care Prices Revealed and Information to Consumers Explained Transparency Act; H.R.6363, the Further Continuing Appropriations and Other Extensions Act, 2024; H.R. 2872, Further Additional Continuing Appropriations and Other Extensions Act, 2024; H.R. 7463, Extension of Continuing Appropriations and Other Matters Act, 2024; H.R. 8247, the Uterine Fibroid Intervention and Gynecological Health Treatment Act of 2024; H.R. 8574, the 340B Affording Care for Communities and Ensuring a Strong Safety-net Act; and H.R. 10337, Expanding the Health Care Workforce Act.
Client expense: $330,000 · Firm income: Not reported
2025 · first_quarter · Health Issues
Sustainability of safety net health systems; social determinants of health; promoting coordinated care; support of telehealth policies; 340B Protect Act, H.R. 4390; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 3281, the Transparent PRICE Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2665, the Supporting Safety Net Hospitals Act; and H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023; H.R. 5378, the Lower Costs, More Transparency Act; S.3548, the Health Care Prices Revealed and Information to Consumers Explained Transparency Act; H.R.6363, the Further Continuing Appropriations and Other Extensions Act, 2024; H.R. 2872, Further Additional Continuing Appropriations and Other Extensions Act, 2024; H.R. 7463, Extension of Continuing Appropriations and Other Matters Act, 2024; H.R. 8247, the Uterine Fibroid Intervention and Gynecological Health Treatment Act of 2024; H.R. 8574, the 340B Affording Care for Communities and Ensuring a Strong Safety-net Act; and H.R. 10337, Expanding the Health Care Workforce Act.
Client expense: $150,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2024 · fourth_quarter · Medicare/Medicaid
Issues related to affordable prescription drugs; Issues related to telehealth authorities; Issues related to health care workforce and staffing; Medicaid Disproportionate Share Hospital payment adjustment program; Issues related to Medicaid coverage; Issues related to hospital reimbursement; 340B Program; Issues related to hospital price transparency; Issues related to Medicare payments; Issues related to Medicare Advantage payment and prior authorization; issues related to rural health reimbursement, including the Medicare Dependent Hospital and Low Volume Hospital programs; physician reimbursement rates; S. 4352/H.R. 8702, the Seniors Timely Access to Care Act; issues related to Program for All-Inclusive Care for the Elderly (PACE); issues related to improving coordination of care for dual eligibles; issues related to site neutral payments; H.R. 3281, the Transparent PRICE Act; issues related to prior authorization, unwarranted claim denials, and payment delays; the Biologics Price Competition and Innovation Act (BPCIA); H.R. 3561, the PATIENT Act; H.R. 6363, Further Continuing Appropriations and Other Extension Act; H.R. 5378, the Lower Costs, More Transparency Act; PL 118-42/H.R. 4366 - Consolidated Appropriations Act, 2024; PL 118-47/H.R. 2882 - Consolidated Appropriations Act, 2024; Issues related to mental and behavioral health; the limit on Medicare payment days for inpatient psychiatric care; the Institutions for Mental Disease exclusion; issues related to extending programs under the SUPPORT for Patients Communities Act; H.R. 10545, the American Relief Act
Client expense: $750,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2024 · fourth_quarter · Health Issues
Sustainability of safety net health systems; social determinants of health; promoting coordinated care; support of telehealth policies; 340B Protect Act, H.R. 4390; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 3281, the Transparent PRICE Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2665, the Supporting Safety Net Hospitals Act; and H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023; H.R. 5378, the Lower Costs, More Transparency Act; S.3548, the Health Care Prices Revealed and Information to Consumers Explained Transparency Act; H.R.6363, the Further Continuing Appropriations and Other Extensions Act, 2024; H.R. 2872, Further Additional Continuing Appropriations and Other Extensions Act, 2024; H.R. 7463, Extension of Continuing Appropriations and Other Matters Act, 2024; H.R. 8247, the Uterine Fibroid Intervention and Gynecological Health Treatment Act of 2024; H.R. 8574, the 340B Affording Care for Communities and Ensuring a Strong Safety-net Act; and H.R. 10337, Expanding the Health Care Workforce Act.
Client expense: $150,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2024 · second_quarter · Medicare/Medicaid
H.R. 1613 / S. 1038, the Drug Price Transparency in Medicaid Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 2880, the Protecting Patients Against PBM Abuses Act; H.R. 1770 / S. 2477, the Equitable Community Access to Pharmacist Services Act; S. 1491, the Pharmacy and Medically Underserved Areas Enhancement Act; H.R. 2816, the PBM Sunshine and Accountability Act; H.R. 3281, the Transparent PRICE Act; H.R. 3282, the Promoting Transparency and Healthy Competition in Medicare Act; H.R. 3561, the PATIENT Act; S. 1967, the Patients Before Middlemen (PBM) Act; S. 2129, the Ensuring Access to Lower-Cost Medicines for Seniors Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S. 2973, the Modernizing and Ensuring PBM Accountability Act; H.R. 5378, the Lower Costs, More Transparency Act; H.R.5385, the Medicare PBM Accountability Act; H.R. 5393, to amend title XVIII of the Social Security Act to ensure fair assessment of pharmacy performance and quality under Medicare part D, and for other purposes; H.R. 5400 / S. 2436, the NO PBMs Act; S.3430,the Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023; Request for Information for "Medicare Transaction Facilitator (MTF) for the Medicare Drug Price Negotiation Program in the Inflation Reduction Act" (IRA; P.L. 117-169); Comments for "Medicare Prescription Payment Plan: Draft Part Two Guidance on Select Topics, Implementation of Section 1860D-2 of the Social Security Act for 2025" (IRA, P.L. 117-169); Comments for Final Rule Document 2022-09375, "Medicare Program, Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs..." (87 FR 27704); Comments for "Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies" (CMS-2024-0006); Request for Information for Bipartisan 340B Senate Working Group SUSTAIN 340B Act Discussion Draft; H.R.4366, the Consolidated Appropriations Act, 2024 H.R.2882, the Further Consolidated Appropriations Act, 2024 Cybersecurity protocols and policies in health care system and the impact on claims processing and reimbursement; Comments to CMS on the implementation of Medicare Part D vaccine coverage under the Inflation Reduction Act (IRA; P.L. 117-169); Comments to CMMI on the Importance of Implementing Reasonable Reimbursement Guardrails for Pharmacies in the Medicare $2 Drug List Model based on the Executive Order on Lowering Prescription Drug Costs for Americans; Comments to HHS and CMS on 2024 NADAC Methodology Changes; Comment on "Medicare Drug Price Negotiation Program: Draft Guidance, Implementation of Sections 1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2027 and Manufacturer Effectuation of the Maximum Fair Price (MFP) in 2026 and 2027.";
Client expense: $340,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Small Business Administration (SBA), White House Office
2024 · fourth_quarter · Health Issues
Issues related to drug pricing reform Changes to Public law 117-1769 Inflation Reduction Act Awareness of implications to patients and research and development of Public law 117-1769 Inflation Reduction Act S. 113 Prescription Pricing for the People Act of 2023 S.127 Pharmacy Benefit Manager Transparency Act HR 830/ S 1375 HELP Copays Act HR 485 Protecting Health Care for All Patients Act HR 5378 Lower Costs, More Transparency Act R 2534 PROTECT 340B Act of 2023 HR 3561 the PATIENT Act S. 1542 DRUG Act S. 1967 PBM Act HR 3503 The NIH Clinical Trials Diversity Act Issues related to cardiovascular disease awareness and treatment Issues related to Federal Trade Commission FDA issues Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Biosimilars reimbursement issues, no specific bill Supply Chain Issues, no specific bill Issues related to 340B Issues related to pharmacy benefit managers Proposed rule: Medicaid Program; Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program HR 4818/ S. 2407 Treat and Reduce Obesity Act S. 2305 Biosimilar Red Tape Elimination Act S. 2129 Ensuring Access to Lower-Cost Medicines for Seniors Act Issues related to PAHPA reauthorization Modernizing and Ensuring PBM Accountability Act (Finance Committee) S. 652/ HR2630 SAFE Step Act S 2474/ HR 5376 Share the Savings with Seniors Act S 2456 Protecting Seniors from High Drug Costs Act HR4881 To amend title XVIII of the Social Security Act to limit cost sharing for drugs under the Medicare program HR 3281 Protecting Patients Against PBM Abuses Act HR 4822 Health Care Price Transparency Act of 2023 S 1339 Pharmacy Benefit Manager Reform Act HR 2679 Pharmacy Benefits Manager Accountability Act HR 4507 Transparency in Coverage Act of 2023 HR 1352 Increasing Access to Biosimilars Act of 2023 HR 2880 Protecting Patients Against PBM Abuses Act Issues pertaining to the implementation of PL 97-414 "Orphan Drug Act," all provisions. HR 5539 Orphan Cures Act HR 5547 Maintaining Investments in New Innovation Act S 3558 BIOSECURE Act HR 7174 Ensuring Pathways to Innovative Cures (EPIC Act) S Res 566 Cholesterol Education Month 2024 HR 7635 340B PATIENTS Act of 2024 H.R. 5391 / S. 2764 The Protecting Patient Access to Cancer and Complex Therapies Act H.R.8574 - 340B Affording Care for Communities and Ensuring a Strong Safety-net Act. HR 5376 Share the Savings With Seniors Act S 3430 Mental Health, Lower Cost Drugs and Extenders Package. BIOCOMPETE (no bill number)- Issues related to prohibiting the export of biotechnology to certain foreign entities HR 8412 Clinical Trial Modernization Act S 5573 Skinny Labels, Big Savings Act HR 10515 American Relief Act
Client expense: $2,780,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2024 · fourth_quarter · Medicare/Medicaid
Issues related to drug pricing reform Changes to Public law 117-1769 Inflation Reduction Act Awareness of implications to patients and research and development of Public law 117-1769 Inflation Reduction Act S. 113 Prescription Pricing for the People Act of 2023 S.127 Pharmacy Benefit Manager Transparency Act HR 485 Protecting Health Care for All Patients Act HR 5378 Lower Costs, More Transparency Act HR 2534 PROTECT 340B act of 2023 HR 3561 the PATIENT act Issues related to cardiovascular disease awareness and treatment Issues related to ESRD Issues related to asthma and self-administered drug list Issues related to reimbursement for biologics/biosimilars Proposed rule: Medicaid Program; Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program HR 4818/ S2407 Treat and Reduce Obesity Act S. 2129 Ensuring Access to Lower-Cost Medicines for Seniors Act Issues related to PAHPA reauthorization Modernizing and Ensuring PBM Accountability Act (Finance Committee) S. 1542/HR 6283 DRUG Act S652 SAFE Step Act HR 3281 Protecting Patients Against PBM Abuses Act HR 4822 Health Care Price Transparency Act of 2023 S 1339 Pharmacy Benefit Manager Reform Act HR 2679 Pharmacy Benefits Manager Accountability Act HR 4507 Transparency in Coverage Act of 2023 S 2474/HR 5376 Share the Savings with Seniors Act S 2456 Protecting Seniors from High Drug Costs Act HR4881 To amend title XVIII of the Social Security Act to limit cost sharing for drugs under the Medicare program HR 1352 Increasing Access to Biosimilars Act of 2023 HR 2880 Protecting Patients Against PBM Abuses Act HR 5547 Maintaining Investments in New Innovation Act HR 7174 Ensuring Pathways to Innovative Cures (EPIC Act) HR 7635 340B PATIENTS Act of 2024 H.R. 5391 / S. 2764 The Protecting Patient Access to Cancer and Complex Therapies Act H.R.8574 - 340B Affording Care for Communities and Ensuring a Strong Safety-net Act. HR 5376 Share the Savings With Seniors Act. S 3430 Mental Health, Lower Cost Drugs and Extenders Package HR 5539 Orphan Cures Act HR 10515 American Relief Act
Client expense: $2,780,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2024 · fourth_quarter · Medicare/Medicaid
H.R. 1613 / S. 1038, the Drug Price Transparency in Medicaid Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 2880, the Protecting Patients Against PBM Abuses Act; H.R. 1770 / S. 2477, the Equitable Community Access to Pharmacist Services Act; S. 1491, the Pharmacy and Medically Underserved Areas Enhancement Act; H.R. 2816, the PBM Sunshine and Accountability Act; H.R. 3281, the Transparent PRICE Act; H.R. 3282, the Promoting Transparency and Healthy Competition in Medicare Act; H.R. 3561, the PATIENT Act; S. 1967, the Patients Before Middlemen (PBM) Act; S. 2129, the Ensuring Access to Lower-Cost Medicines for Seniors Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S. 2973, the Modernizing and Ensuring PBM Accountability Act; H.R. 5378, the Lower Costs, More Transparency Act; H.R.5385, the Medicare PBM Accountability Act; H.R. 5393, to amend title XVIII of the Social Security Act to ensure fair assessment of pharmacy performance and quality under Medicare part D, and for other purposes; H.R. 5400 / S. 2436, the NO PBMs Act; S.3430,the Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023; Request for Information for "Medicare Transaction Facilitator (MTF) for the Medicare Drug Price Negotiation Program in the Inflation Reduction Act" (IRA; P.L. 117-169); Comments for "Medicare Prescription Payment Plan: Draft Part Two Guidance on Select Topics, Implementation of Section 1860D-2 of the Social Security Act for 2025" (IRA, P.L. 117-169); Comments for Final Rule Document 2022-09375, "Medicare Program, Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs..." (87 FR 27704); Comments for "Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies" (CMS-2024-0006); Request for Information for Bipartisan 340B Senate Working Group SUSTAIN 340B Act Discussion Draft; H.R.4366, the Consolidated Appropriations Act, 2024 H.R.2882, the Further Consolidated Appropriations Act, 2024 Cybersecurity protocols and policies in health care system and the impact on claims processing and reimbursement; Comments to CMS on the implementation of Medicare Part D vaccine coverage under the Inflation Reduction Act (IRA; P.L. 117-169); Comments to CMMI on the Importance of Implementing Reasonable Reimbursement Guardrails for Pharmacies in the Medicare $2 Drug List Model based on the Executive Order on Lowering Prescription Drug Costs for Americans; Comments to HHS and CMS on 2024 NADAC Methodology Changes; Comment to CMS on "Medicare Drug Price Negotiation Program: Draft Guidance, Implementation of Sections 1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2027 and Manufacturer Effectuation of the Maximum Fair Price (MFP) in 2026 and 2027."; H.R. 9096, the Pharmacists Fight Back Act; Long Term Care at Home Pharmacy Services in Medicare; Regulating fair and common-sense contracting guardrails between Part D plans/PBMs, and pharmacies; Comments to CMS on Proposed Rule Re: Medicare and Medicaid Programs; CY 2025 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; Medicare Prescription Drug Inflation Rebate Program; and Medicare Overpayments [CMS-1807-P]; H.R.4758, the Accelerating Kids Access to Care Act; H.R. 8107, the Ensuring Access to Medicaid Buy-in Programs Act of 2024; Comments to CMS on Draft Guidance Re: Medicare Drug Price Negotiation Program: Draft Guidance, Implementation of Sections 1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2027 and Manufacturer Effectuation of the Maximum Fair Price (MFP) in 2026 and 2027; Request for Information to CMS on "Medicare $2 Drug list Model" (Executive Order 14087 of October 14, 2022); H.R.5074/S.5410, the Kidney PATIENT Act; H.R.4104/S.1976, the Preserving Patient Access to Home Infusion Act; H.R.10545, the American Relief Act, 2025;
Client expense: $412,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Small Business Administration (SBA), White House Office
2024 · fourth_quarter · Health Issues
Issues regarding childrens health care coverage and access to care under Medicaid, CHIP, the Exchanges, TRICARE, and private insurance Issues regarding the annual Notice of Benefit and Payment Parameters for the Exchanges and private insurance Issues regarding childrens mental health and the national emergency in childrens mental health, including mental health parity, the mental health workforce and related access issues. Issue regarding Medicaid supplemental payments and directed payments Issues related to Health Information Technology, interoperability, information blocking, and cybersecurity Issues regarding the importance of Medicaid to children, including military and veteran families Issues regarding Medicaid support for providers caring for children on Medicaid, including DSH payments Issues regarding Children's Hospitals Graduate Medical Education (CHGME) program and funding Issues related to 340B Drug Pricing Program, prescription drug pricing, drug shortages, high-cost drugs/therapies and pharmaceutical supply chain, including H.R. 3290 Issues related to pediatric workforce, Medicare GME, the Pediatric Specialty Loan Repayment Program, and Title VII and VIII Issues regarding Organ Procurement and Transplantation Network Issues regarding site neutrality, facility fees, and price transparency in health care Issues regarding pediatric pandemic and disaster preparedness and response and emergency preparedness Issues regarding food security and nutrition Issues regarding drugs and medical device shortages and high costs, including IV fluid shortages and infant formula Issues related to the regulation of laboratory-developed tests Issues regarding prescribing of drugs via telehealth Issues related to mental health services in schools Issues related to pediatric cancer and the Moonshot Issues regarding Artificial Intelligence (AI) Issues regarding oversight and implementation of EPSDT H.R. 2412 The Helping Kids Cope Act S.2372/HR. 4758 - Accelerating Kids Access to Care Act H.R. 1397, Telehealth Improvement for Kids Essential Services (TIKES) Act H.R. 7623/ S. 3967, Telehealth Modernization Act Issues involving Site Neutral payment legislation, including H.R. 3281 and H.R. 3561 S. 3029/H.R. 6085 PREEMIE Reauthorization Act H.R. 2584/S.2768, Safety form Violence for Healthcare employees (Save) Act S. 1409, Kids Online Safety Act H.R. 6663/S. 3364, Kid PROOF Act of 2023 H.R. 6664 Innovation for Pediatric Drugs Act of 2023 H.R. 7808, the Early Action and Responsiveness Lifts Youth (EARLY) Minds Act H.R. 7153/S. 3679 Dr. Lorna Breen Health Care Provider Protection Reauthorization Act S. 3757 Congenital Heart Futures Reauthorization Act of 2024 H.R. 6960 Emergency Medical Services for Children Reauthorization Act of 2024 H.R. 3391 Gabriella Miller Kids First Research Act 2.0 H.R. 6963 Pediatric Cancer Drug Supply Act H.R. 3433/ S. 2897, Give Kids A Chance Act H.R. 7384, Creating Hope Reauthorization Act. H.R. 6664/S. 4905, Innovation in Pediatric Drugs Act
Client expense: $1,600,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Drug Enforcement Administration (DEA), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Labor, Dept of (DOL), Office of Management & Budget (OMB), SENATE
2024 · fourth_quarter · Pharmacy
Issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691, Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R. 2880, Protecting Patients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S. 2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of 2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act; H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 3285, Fairness for Patient Medications Act; S. 2973 Modernizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0); H.R.3285 - Fairness for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 7535, Prescription Drug Supply Chain Pricing Transparency Act; S. 2305, Biosimilar Red Tape Elimination Act; H.R. 6986/S.3583, to address patent thickets; H.R. 8261, the Preserving Telehealth, Hospital, and Ambulance Access Act; Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future of 340B Act (SUSTAIN 340B Act); S.150, the Affordable Prescription Drug for Patients Act; S. 142, the Preserve Access to Affordable Generics and Biosimilars Act; S. 5503, H.R. 10362, the Patients Before Monopolies (PBM) Act; P.L. No: 118-158 and draft FY2025 Continuing Resolution, issues related to PBMs.
Client expense: $1,420,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · fourth_quarter · Health Issues
Sustainability of safety net health systems; social determinants of health; promoting coordinated care; support of telehealth policies; 340B Protect Act, H.R. 4390; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 3281, the Transparent PRICE Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2665, the Supporting Safety Net Hospitals Act; and H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023; H.R. 5378, the Lower Costs, More Transparency Act; S.3548, the Health Care Prices Revealed and Information to Consumers Explained Transparency Act; H.R.6363, the Further Continuing Appropriations and Other Extensions Act, 2024; H.R. 2872, Further Additional Continuing Appropriations and Other Extensions Act, 2024; H.R. 7463, Extension of Continuing Appropriations and Other Matters Act, 2024; H.R. 8247, the Uterine Fibroid Intervention and Gynecological Health Treatment Act of 2024; H.R. 8574, the 340B Affording Care for Communities and Ensuring a Strong Safety-net Act; and H.R. 10337, Expanding the Health Care Workforce Act.
Client expense: $130,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2024 · fourth_quarter · Medicare/Medicaid
Issues related to affordable prescription drugs; Issues related to telehealth authorities; Issues related to health care workforce and staffing; Medicaid Disproportionate Share Hospital payment adjustment program; Issues related to Medicaid coverage; Issues related to hospital reimbursement; 340B Program; Issues related to hospital price transparency; Issues related to Medicare payments; Issues related to Medicare Advantage payment and prior authorization; issues related to rural health reimbursement, including the Medicare Dependent Hospital and Low Volume Hospital programs; physician reimbursement rates; S. 4352/H.R. 8702, the Seniors Timely Access to Care Act; issues related to Program for All-Inclusive Care for the Elderly (PACE); issues related to improving coordination of care for dual eligibles; issues related to site neutral payments; H.R. 3281, the Transparent PRICE Act; issues related to prior authorization, unwarranted claim denials, and payment delays; the Biologics Price Competition and Innovation Act (BPCIA); H.R. 3561, the PATIENT Act; H.R. 6363, Further Continuing Appropriations and Other Extension Act; H.R. 5378, the Lower Costs, More Transparency Act; PL 118-42/H.R. 4366 - Consolidated Appropriations Act, 2024; PL 118-47/H.R. 2882 - Consolidated Appropriations Act, 2024; Issues related to mental and behavioral health; the limit on Medicare payment days for inpatient psychiatric care; the Institutions for Mental Disease exclusion; issues related to extending programs under the SUPPORT for Patients Communities Act; H.R. 10545, the American Relief Act
Client expense: $750,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2024 · fourth_quarter · Health Issues
Transparency (surprise medical bills; public posting of hospital charges) 340B Drug Pricing Program (H.R. 3290) Rural health care innovation (PA Rural Health Model) Public Health Emergency designation SAVE Act (H.R. 2584) Fairness for Rural Teaching Hospitals Act (H.R.2433) Public Service Loan Forgiveness program/physician federal loan forgiveness Healthcare Workforce Behavioral health PATIENT Act of 2023 (H.R.3561) Nurse Staffing Standards for Hospital Patient Safety and Quality Care Act (S.1113, H.R.2530) CHGME Youth behavioral health Electronic health records Pandemic and All-Hazards Preparedness Reauthorization Act Nursing and allied health education (NAHE) program Bipartisan Primary Care and Health Workforce Act (S.2840) Transparent PRICE Act (H.R.3281) Save Americas Rural Hospitals Act (H.R.833) Supporting Safety Net Hospitals Act (H.R.2665) Patient Access to Higher Quality Care Act (H.R.977/S.470) FEMA Covid-19 reimbursement Health Care Price Transparency Act (H.R.4822) Providers and Payers Compete Act (H.R.3284) Lower Costs, More Transparency Act (H.R.5378) Health Care Prices Revealed and Information to Consumers Explained Transparency Act (S.3548) Medical and Nurse Licensure Compact Health care consolidation, mergers and acquisitions Accelerating Kids Access to Care Act (H.R. 4758, S.2372)
Client expense: $60,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · fourth_quarter · Health Issues
Legislation and regulation related to health care delivery and health insurance coverage, mental health and substance use disorder care and coverage, the transition out of the COVID-19 pandemic and electronic health information/technology. H.R. 4527 Health DATA Act S. 3679, Dr. Lorna Breen Health Care Provider Protection Reauthorization Act H.R. 5378 the Lower Costs, More Transparency Act S.3548 - Health Care Prices Revealed and Information to Consumers Explained Transparency Act S.3430 - An original bill to amend titles XVIII and XIX of the Social Security Act to expand the mental health care workforce and services, reduce prescription drug costs, and extend certain expiring provisions under Medicare and Medicaid, and for other purposes. HR 3305 & S. 1606 Black Maternal Health Momnibus Act HR 4822 Health Care Price Transparency Act HR 3284 Providers and Payers COMPETE Act HR 2840 Bipartisan Primary Care and Health Workforce Act HR 4818 Treat and Reduce Obesity Act of 2023 S. 2333 Pandemic and All Hazards Preparedness and Response Act H.R. 4421 Preparing for All Hazards and Pathogens Reauthorization Act H.R. 3561, PATIENT Act of 2023 H.R. 3281, the Transparent PRICE Act H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information H.R. 2868 Association Health Plans Act H.R. 2813 Self-Insurance Protection Act H.R. 3799 CHOICE Arrangement Act H.R. 3432, Telemental Health Care Access Act H.R.824, Telehealth Benefit Expansion for Workers Act of 2023 H.R. 4189, S. 2016, CONNECT for Health Act S. 923, Better Mental Health Care for Americans Act H.R. 3120, Healthy Competition for Better Care Act H.R. 1843 Telehealth Expansion Act of 2023 S.954 - 118th Congress (2023-2024)A bill to provide for appropriate cost-sharing for insulin products covered under private health plans, and to establish a program to support health care providers and pharmacies in providing discounted insulin products to uninsured individuals. H.R.10445 - Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act, 2025 H.R.10515 - American Relief Act, 2025 H.R.10545 - American Relief Act, 2025 H.R. 9774 & S. 5194 - Health Care Affordability Act of 2024 H.R. 3120 & S. 1451 - Healthy Competition for Better Care Act
Client expense: $220,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2024 · fourth_quarter · Health Issues
Q4 Lobbying Report (Oct.1 -Dec. 31) HCR Transparency (surprise medical bills; public posting of hospital charges) 340B Drug Pricing Program Resident Physician Shortage Act of 2023 (H.R. 2389) No Surprises Act regulations Food and Drug Amendments No Surprise Bills for New Moms Act (H.R. 3387) Securing the U.S. Organ Procurement and Transplantation Network Act (H.R. 2544) Promoting Access to Treatments and Increasing Extremely Needed Transparency Act (H.R. 3561) Medicaid VBPs for Patients (MVP) Act (H.R. 2666) Providers and Payers COMPETE Act (H.R. 3284) To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program (H.R. 3290) Transparent PRICE Act (H.R. 3281/H.R. 2691)) Resident Physician Shortage Reduction (S. 1302) Medical Student Education Authorization Act (H.R. 3046) Save Americas Rural Hospitals Act (H.R. 833) Chronic Care Management Improvement Act (H.R. 2829) Safety From Violence for Healthcare Employees Act (H.R. 2584) Supporting Safety Net Hospitals Act (H.R. 2665) Patient Access to Higher Quality Health Care Act (H.R. 977/S.470) FEMA re: COVID-19 related reimbursement Public Health Guidance Transparency and Accountability Act of 2023 (H.R. 4529) Public Health Emergency Congressional Review Act (H.R. 4381) CDC Leadership Accountability Act of 2023 (H.R. 3813) Preparing for All Hazards and Pathogens Reauthorization Act (H.R. 4421) Preparedness and Response Reauthorization Act (H.R. 4420) Childrens Hospital GME Support Reauthorization Act of 2023 (H.R. 3887) Health Care Price Transparency Act of 2023 (H.R. 4822) Providers and Payers COMPETE Act (H.R. 3284) Lower Costs, More Transparency Act (H.R. 5378 Transparency in Coverage Act (H.R. 4507) GOLD Card Act of 2023 (H.R. 4968) No Fees for EFTs Act (H.R.6487) Rural Health Care Facilities Revitalization Act (H.R. 5989) Dr. Lorna Breen Health Care Provider Protection Reauthorization Act (H.R. 7153) To amend title XVIII of the Social Security Act to establish a definition of essential health system in statute (H.R. 7397) Substance Use Disorder Workforce Act (H.R. 7050) 340B PATIENTS Act (H.R. 7635) The 340B Affording Care for Communities and Ensuring a Strong Safety-net (ACCESS) Act (H.R. 8574) Improving Seniors Access to Timely Care Act (H.R. 8702/S.4532) The Preserving Emergency Access in Key Sites (PEAKS) Act (H.R. 7931) Rural Health Care Facilities Revitalization Act (H.R. 5989) MMM Accelerated and Advance Payment Program repayment flexibility Graduate Medical Education (GME) funding Telehealth flexibilities and payment Annual Prospective Payment System Rules Organ acquisition payment policies Californias Medicaid Hospital Quality Assurance Fee Program Medicare Advantage BUD FY 2025 Appropriations bills Nursing and allied health workforce funding FY 2025 budget request Further Continuing Appropriations and Other Extensions Act (H.R. 6363) Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R. 5894) Tax Relief for American Families and Workers Act of 2024 (H.R. 7024) Extension of Continuing Appropriations and Other Matters Act, 2024 (H.R. 7463) Submitted Comments Regulatory Comment Letters SUBJECT: CMS-10913, Medicare Part C Utilization Management Annual Data Submission and Audit Protocol Data Request; Notice, Agency Information Collection Activities: Proposed Collection; Comment Request; Federal Register (Vol 89, No 145), September 10, 2024
Client expense: $300,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), SENATE, Social Security Administration (SSA)
2024 · fourth_quarter · Health Issues
Monitoring legislation that could impact access to hospital or physician care, particularly related to the Medicare and Medicaid programs and the 340B drug discount program. In addition, monitoring legislation that could impact health care workforce training or behavioral health services or medical research or related to the use of telehealth. Specific legislation includes: legislation related to outpatient departments and unique identification numbers (H.R. 3237)", The "Resident Physician Shortage Reduction Act (H.R. 2389/S.1302)", the "Patient Act (H.R. 3561)", legislation related to the 340B drug discount program (H.R. 3290), the "Transparent Price Act (H.R. 3281)", the "Lower Costs, More Transparency Act (H.R. 5378)", "Educate Act (H.R. 7725)" and H.R. 10545, a bill making further continuing appropriations for the fiscal year ending September 30, 2025, and for other purposes.
Client expense: Not reported · Firm income: $33,750
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · fourth_quarter · Health Issues
Support S. 127 PBM Transparency Act; support S. 1001/H.R. 1843 Telehealth Expansion Act; support H.R. 3561 PATIENT Act (formerly H.R. 3281 Transparent Price Act); support S. 1339 PBM Reform Act; support H.R. 5378 Lower Costs, More Transparency Act.
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · third_quarter · Health Issues
Transparency (surprise medical bills; public posting of hospital charges) 340B Drug Pricing Program (H.R. 3290) Rural health care innovation (PA Rural Health Model) Public Health Emergency designation SAVE Act (H.R. 2584) Fairness for Rural Teaching Hospitals Act (H.R.2433) Public Service Loan Forgiveness program/physician federal loan forgiveness Healthcare Workforce Behavioral health PATIENT Act of 2023 (H.R.3561) Nurse Staffing Standards for Hospital Patient Safety and Quality Care Act (S.1113, H.R.2530) CHGME Youth behavioral health Electronic health records Pandemic and All-Hazards Preparedness Reauthorization Act Nursing and allied health education (NAHE) program Bipartisan Primary Care and Health Workforce Act (S.2840) Transparent PRICE Act (H.R.3281) Save Americas Rural Hospitals Act (H.R.833) Supporting Safety Net Hospitals Act (H.R.2665) Patient Access to Higher Quality Care Act (H.R.977/S.470) FEMA Covid-19 reimbursement Health Care Price Transparency Act (H.R.4822) Providers and Payers Compete Act (H.R.3284) Lower Costs, More Transparency Act (H.R.5378) Health Care Prices Revealed and Information to Consumers Explained Transparency Act (S.3548) Medical and Nurse Licensure Compact Health care consolidation, mergers and acquisitions Accelerating Kids Access to Care Act (H.R. 4758, S.2372)
Client expense: $60,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · third_quarter · Health Issues
H.R. 4527 Health DATA Act S. 3679, Dr. Lorna Breen Health Care Provider Protection Reauthorization Act H.R. 5378 the Lower Costs, More Transparency Act S.3548 - Health Care Prices Revealed and Information to Consumers Explained Transparency Act S.3430 - An original bill to amend titles XVIII and XIX of the Social Security Act to expand the mental health care workforce and services, reduce prescription drug costs, and extend certain expiring provisions under Medicare and Medicaid, and for other purposes. HR 3305 & S. 1606 Black Maternal Health Momnibus Act HR 4822 Health Care Price Transparency Act HR 3284 Providers and Payers COMPETE Act HR 2840 Bipartisan Primary Care and Health Workforce Act HR 4818 Treat and Reduce Obesity Act of 2023 S. 2333 Pandemic and All Hazards Preparedness and Response Act H.R. 4421 Preparing for All Hazards and Pathogens Reauthorization Act H.R. 3561, PATIENT Act of 2023 H.R. 3281, the Transparent PRICE Act H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information H.R. 2868 Association Health Plans Act H.R. 2813 Self-Insurance Protection Act H.R. 3799 CHOICE Arrangement Act H.R. 3432, Telemental Health Care Access Act H.R.824, Telehealth Benefit Expansion for Workers Act of 2023 H.R. 4189, S. 2016, CONNECT for Health Act S. 923, Better Mental Health Care for Americans Act H.R. 3120, Healthy Competition for Better Care Act H.R. 1843 Telehealth Expansion Act of 2023 Legislation and regulation related to health care delivery and health insurance coverage, mental health and substance use disorder care and coverage, the transition out of the COVID-19 pandemic and electronic health information/technology. S.954 - 118th Congress (2023-2024)A bill to provide for appropriate cost-sharing for insulin products covered under private health plans, and to establish a program to support health care providers and pharmacies in providing discounted insulin products to uninsured individuals. a
Client expense: $210,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2024 · third_quarter · Pharmacy
Issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, Protecting Patients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of 2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modernizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0); H.R.3285 - Fairness for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R.7535, Prescription Drug Supply Chain Pricing Transparency Act; S. 2780, Medication Affordability and Patent Integrity Act; S. 2305, Biosimilar Red Tape Elimination Act; H.R. 6986/S.3583, to address patent thickets; H.R. 8261, the Preserving Telehealth, Hospital, and Ambulance Access Act; Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future of 340B Act (SUSTAIN 340B Act); H.R. 8574, 340B Affording Care for Communities and Ensuring a Strong Safety-Net Act (340B ACCESS Act); S.150, the Affordable Prescription Drug for Patients Act; S. 142, the Preserve Access to Affordable Generics and Biosimilars Act.
Client expense: $1,720,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · third_quarter · Medicare/Medicaid
Issues related to drug pricing reform Changes to Public law 117-1769 Inflation Reduction Act Awareness of implications to patients and research and development of Public law 117-1769 Inflation Reduction Act S. 113 Prescription Pricing for the People Act of 2023 S.127 Pharmacy Benefit Manager Transparency Act HR 485 Protecting Health Care for All Patients Act HR 5378 Lower Costs, More Transparency Act HR 2534 PROTECT 340B act of 2023 HR 3561 the PATIENT act Issues related to cardiovascular disease awareness and treatment Issues related to ESRD Issues related to asthma and self-administered drug list Issues related to reimbursement for biologics/biosimilars Proposed rule: Medicaid Program; Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program HR 4818/ S2407 Treat and Reduce Obesity Act S. 2129 Ensuring Access to Lower-Cost Medicines for Seniors Act Issues related to PAHPA reauthorization Modernizing and Ensuring PBM Accountability Act (Finance Committee) S. 1542/HR 6283 DRUG Act S652 SAFE Step Act HR 3281 Protecting Patients Against PBM Abuses Act HR 4822 Health Care Price Transparency Act of 2023 S 1339 Pharmacy Benefit Manager Reform Act HR 2679 Pharmacy Benefits Manager Accountability Act HR 4507 Transparency in Coverage Act of 2023 S 2474/HR 5376 Share the Savings with Seniors Act S 2456 Protecting Seniors from High Drug Costs Act HR4881 To amend title XVIII of the Social Security Act to limit cost sharing for drugs under the Medicare program HR 1352 Increasing Access to Biosimilars Act of 2023 HR 2880 Protecting Patients Against PBM Abuses Act HR 5547 Maintaining Investments in New Innovation Act HR 7174 Ensuring Pathways to Innovative Cures (EPIC Act) HR 7635 340B PATIENTS Act of 2024 H.R. 5391 / S. 2764 The Protecting Patient Access to Cancer and Complex Therapies Act H.R.8574 - 340B Affording Care for Communities and Ensuring a Strong Safety-net Act. HR 5376 Share the Savings With Seniors Act. S 3430 Mental Health, Lower Cost Drugs and Extenders Package HR 5539 Orphan Cures Act
Client expense: $2,770,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2024 · third_quarter · Health Issues
Issues related to drug pricing reform Changes to Public law 117-1769 Inflation Reduction Act Awareness of implications to patients and research and development of Public law 117-1769 Inflation Reduction Act S. 113 Prescription Pricing for the People Act of 2023 S.127 Pharmacy Benefit Manager Transparency Act HR 830/ S 1375 HELP Copays Act HR 485 Protecting Health Care for All Patients Act HR 5378 Lower Costs, More Transparency Act R 2534 PROTECT 340B Act of 2023 HR 3561 the PATIENT Act S. 1542 DRUG Act S. 1967 PBM Act HR 3503 The NIH Clinical Trials Diversity Act Issues related to cardiovascular disease awareness and treatment Issues related to Federal Trade Commission FDA issues Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Biosimilars reimbursement issues, no specific bill Supply Chain Issues, no specific bill Issues related to 340B Issues related to pharmacy benefit managers Proposed rule: Medicaid Program; Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program HR 4818/ S. 2407 Treat and Reduce Obesity Act S. 2305 Biosimilar Red Tape Elimination Act S. 2129 Ensuring Access to Lower-Cost Medicines for Seniors Act Issues related to PAHPA reauthorization Modernizing and Ensuring PBM Accountability Act (Finance Committee) S. 652/ HR2630 SAFE Step Act S 2474/ HR 5376 Share the Savings with Seniors Act S 2456 Protecting Seniors from High Drug Costs Act HR4881 To amend title XVIII of the Social Security Act to limit cost sharing for drugs under the Medicare program HR 3281 Protecting Patients Against PBM Abuses Act HR 4822 Health Care Price Transparency Act of 2023 S 1339 Pharmacy Benefit Manager Reform Act HR 2679 Pharmacy Benefits Manager Accountability Act HR 4507 Transparency in Coverage Act of 2023 HR 1352 Increasing Access to Biosimilars Act of 2023 HR 2880 Protecting Patients Against PBM Abuses Act Issues pertaining to the implementation of PL 97-414 "Orphan Drug Act," all provisions. HR 5539 Orphan Cures Act HR 5547 Maintaining Investments in New Innovation Act S 3558 BIOSECURE Act HR 7174 Ensuring Pathways to Innovative Cures (EPIC Act) S Res 566 Cholesterol Education Month 2024 HR 7635 340B PATIENTS Act of 2024 H.R. 5391 / S. 2764 The Protecting Patient Access to Cancer and Complex Therapies Act H.R.8574 - 340B Affording Care for Communities and Ensuring a Strong Safety-net Act. HR 5376 Share the Savings With Seniors Act S 3430 Mental Health, Lower Cost Drugs and Extenders Package. BIOCOMPETE (no bill number)- Issues related to prohibiting the export of biotechnology to certain foreign entities HR 8412 Clinical Trial Modernization Act
Client expense: $2,770,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2024 · third_quarter · Health Issues
Issues regarding childrens health care coverage and access to care under Medicaid, CHIP, the Exchanges, and private insurance Issues regarding the annual Notice of Benefit and Payment Parameters for the Exchanges and private insurance Issues regarding childrens and mothers health specifically continuous eligibility for children in Medicaid and CHIP, CHIP permanency Issues regarding childrens mental health and the national emergency in childrens mental health, including mental health parity, the mental health workforce and related access issues. Issue regarding Medicaid supplemental payments and directed payments Issues related to Health Information Technology, interoperability, information blocking, and cybersecurity Issues regarding the importance of Medicaid to children, including military and veteran families Issues regarding Medicaid support for providers caring for children on Medicaid, including DSH payments Issues regarding Children's Hospitals Graduate Medical Education (CHGME) program and funding Issues related to 340B Drug Pricing Program, prescription drug pricing, drug shortages, high-cost drugs/therapies and pharmaceutical supply chain, including H.R. 3290 Issues related to pediatric workforce, Medicare GME, the Pediatric Specialty Loan Repayment Program, and Title VII and VIII Issues regarding Organ Procurement and Transplantation Network Issues regarding site neutrality and price transparency in health care Issues regarding pediatric pandemic and disaster preparedness and response and emergency preparedness Issues regarding food security and nutrition Issues regarding drugs and medical device shortages and high costs Issues related to the regulation of laboratory-developed tests Issues regarding prescribing of drugs via telehealth Issues related to mental health services in schools Issues related to pediatric cancer and the Moonshot Issues regarding Artificial Intelligence (AI) Issues regarding oversight and implementation of EPSDT H.R. 2412 The Helping Kids Cope Act S.2372/HR. 4758 - Accelerating Kids Access to Care Act H.R. 1397, Telehealth Improvement for Kids Essential Services (TIKES) Act H.R. 7623/ S. 3967, Telehealth Modernization Act Issues involving Site Neutral payment legislation, including H.R. 3281 and H.R. 3561 S. 1774/H.R. 3761 the Assist Act H.R. 2584/S.2768, Safety form Violence for Healthcare employees (Save) Act S. 1409, Kids Online Safety Act H.R. 6663/S. 3364, Kid PROOF Act of 2023 H.R. 6664 Innovation for Pediatric Drugs Act of 2023 H.R. 7808, the Early Action and Responsiveness Lifts Youth (EARLY) Minds Act H.R. 6960 Emergency Medical Services for Children Reauthorization Act of 2024 H.R. 3391 Gabriella Miller Kids First Research Act 2.0 H.R. 6963 Pediatric Cancer Drug Supply Act H.R. 3433/ S. 2897, Give Kids A Chance Act H.R. 7384, Creating Hope Reauthorization Act. H.R. 6664/S. 4905, Innovation in Pediatric Drugs Act H.R: 4714: Pediatricians Accelerate Childhood Therapies Act of 2023 S. 0251 340B PATIENTS Act of 2024 H.R. 9577 Stabilization to Prevent (STOP) Suicide Act.
Client expense: $1,170,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Labor, Dept of (DOL), Office of Management & Budget (OMB), SENATE
2024 · third_quarter · Medicare/Medicaid
Issues related to affordable prescription drugs; Issues related to telehealth authorities; Issues related to health care workforce and staffing; Medicaid Disproportionate Share Hospital payment adjustment program; Issues related to Medicaid coverage; Issues related to hospital reimbursement; 340B Program; Issues related to hospital price transparency; Issues related to Medicare payments; Issues related to Medicare Advantage payment and prior authorization; issues related to rural health; S. 4352/H.R. 8702, the Seniors Timely Access to Care Act; Future Advancement of Academic Nursing (FAAN) Act; Expanding Care in the Home Act; H.R. 1770, Equitable Access to Pharmacy Services Act; issues related to Program for All-Inclusive Care for the Elderly (PACE); issues related to improving coordination of care for dual eligibles; issues related to site neutral payments; H.R. 3281, the Transparent PRICE Act; issues related to prior authorization, unwarranted claim denials, and payment delays; the Biologics Price Competition and Innovation Act (BPCIA); H.R. 3561, the PATIENT Act; H.R. 6363, Further Continuing Appropriations and Other Extension Act; H.R. 5378, the Lower Costs, More Transparency Act; PL 118-42/H.R. 4366 - Consolidated Appropriations Act, 2024; PL 118-47/H.R. 2882 - Consolidated Appropriations Act, 2024; Issues related to mental and behavioral health; the limit on Medicare payment days for inpatient psychiatric care; the Institutions for Mental Disease exclusion; issues related to extending programs under the SUPPORT for Patients Communities Act.
Client expense: $800,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2024 · third_quarter · Health Issues
Sustainability of safety net health systems; social determinants of health; promoting coordinated care; support of telehealth policies; 340B Protect Act, H.R. 4390; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 3281, the Transparent PRICE Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2665, the Supporting Safety Net Hospitals Act; and H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023; H.R. 5378, the Lower Costs, More Transparency Act; S.3548, the Health Care Prices Revealed and Information to Consumers Explained Transparency Act; H.R.6363, the Further Continuing Appropriations and Other Extensions Act, 2024; H.R. 2872, Further Additional Continuing Appropriations and Other Extensions Act, 2024; H.R. 7463, Extension of Continuing Appropriations and Other Matters Act, 2024; H.R. 8247, the Uterine Fibroid Intervention and Gynecological Health Treatment Act of 2024; and H.R. 8574, the 340B Affording Care for Communities and Ensuring a Strong Safety-net Act.
Client expense: $130,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2024 · third_quarter · Health Issues
Q3 Lobbying Report (July 1-Sept. 10) HCR Transparency (surprise medical bills; public posting of hospital charges) 340B Drug Pricing Program Resident Physician Shortage Act of 2023 (H.R. 2389) No Surprises Act regulations Food and Drug Amendments No Surprise Bills for New Moms Act (H.R. 3387) Securing the U.S. Organ Procurement and Transplantation Network Act (H.R. 2544) Promoting Access to Treatments and Increasing Extremely Needed Transparency Act (H.R. 3561) Medicaid VBPs for Patients (MVP) Act (H.R. 2666) Providers and Payers COMPETE Act (H.R. 3284) To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program (H.R. 3290) Transparent PRICE Act (H.R. 3281/H.R. 2691)) Resident Physician Shortage Reduction (S. 1302) Medical Student Education Authorization Act (H.R. 3046) Save Americas Rural Hospitals Act (H.R. 833) Chronic Care Management Improvement Act (H.R. 2829) Safety From Violence for Healthcare Employees Act (H.R. 2584) Supporting Safety Net Hospitals Act (H.R. 2665) Patient Access to Higher Quality Health Care Act (H.R. 977/S.470) FEMA re: COVID-19 related reimbursement Public Health Guidance Transparency and Accountability Act of 2023 (H.R. 4529) Public Health Emergency Congressional Review Act (H.R. 4381) CDC Leadership Accountability Act of 2023 (H.R. 3813) Preparing for All Hazards and Pathogens Reauthorization Act (H.R. 4421) Preparedness and Response Reauthorization Act (H.R. 4420) Childrens Hospital GME Support Reauthorization Act of 2023 (H.R. 3887) Health Care Price Transparency Act of 2023 (H.R. 4822) Providers and Payers COMPETE Act (H.R. 3284) Lower Costs, More Transparency Act (H.R. 5378 Transparency in Coverage Act (H.R. 4507) GOLD Card Act of 2023 (H.R. 4968) No Fees for EFTs Act (H.R.6487) Rural Health Care Facilities Revitalization Act (H.R. 5989) Dr. Lorna Breen Health Care Provider Protection Reauthorization Act (H.R. 7153) To amend title XVIII of the Social Security Act to establish a definition of essential health system in statute (H.R. 7397) Substance Use Disorder Workforce Act (H.R. 7050) 340B PATIENTS Act (H.R. 7635) The 340B Affording Care for Communities and Ensuring a Strong Safety-net (ACCESS) Act (H.R. 8574) Improving Seniors Access to Timely Care Act (H.R. 8702/S.4532) The Preserving Emergency Access in Key Sites (PEAKS) Act (H.R. 7931) Rural Health Care Facilities Revitalization Act (H.R. 5989) MMM Accelerated and Advance Payment Program repayment flexibility Graduate Medical Education (GME) funding Telehealth flexibilities and payment Annual Prospective Payment System Rules Organ acquisition payment policies Californias Medicaid Hospital Quality Assurance Fee Program Medicare Advantage BUD FY 2024 Appropriations bills Nursing and allied health workforce funding FY 2024 budget request Further Continuing Appropriations and Other Extensions Act (H.R. 6363) Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R. 5894) Tax Relief for American Families and Workers Act of 2024 (H.R. 7024) Extension of Continuing Appropriations and Other Matters Act, 2024 (H.R. 7463) Submitted Comments Regulatory Comment Letters SUBJECT: CMS-1809-P, Medicare and Medicaid Programs: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems; Quality Reporting Programs, including the Hospital Inpatient Quality Reporting Program; Health and Safety Standards for Obstetrical Services in Hospitals and Critical Access Hospitals; Prior Authorization; Requests for Information; Medicaid and CHIP Continuous Eligibility; Medicaid Clinic Services Four Walls Exceptions; Individuals Currently or Formerly in Custody of Penal Authorities; Revision to Medicare Special Enrollment Period for Formerly Incarcerated Individuals; and All-Inclusive Rate Add-On Payment for High-Cost Drugs Provided by Indian Health Service and Tribal Facilities, (Vol 89, No 140), July 22, 2024 SUBJECT: CMS-1803-P, Medicare Program; Calendar Year (CY) 2025 Home Health Prospective Payment System (HH PPS) Rate Update; HH Quality Reporting Program Requirements; HH Value-Based Purchasing Expanded Model Requirements; Home Intravenous Immune Globulin (IVIG) Items and Services Rate Update; and Other Medicare Policies, Federal Register (Vol. 89, No. 128), July 3, 2024 SUBJECT: CMS-5535-P, Medicare Program; Alternative Payment Model Updates and the Increasing Organ Transplant Access (IOTA) Model, Federal Register (Vol. 89, No. 97), May 17, 2024 Legislative Comment Letters Letter to HHS on Johnson & Johnson's Proposed Changes to 340B Drug Discount Program, Sept. 19, 2024
Client expense: $380,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), SENATE, Social Security Administration (SSA)
2024 · third_quarter · Health Issues
Monitoring legislation that could impact access to hospital or physician care, particularly related to the Medicare and Medicaid programs and the 340B drug discount program. In addition, monitoring legislation that could impact health care workforce training or behavioral health services or medical research or related to the use of telehealth. Specific legislation includes: legislation related to outpatient departments and unique identification numbers (H.R. 3237)", The "Resident Physician Shortage Reduction Act (H.R. 2389/S.1302)", the "Patient Act (H.R. 3561)", legislation related to the 340B drug discount program (H.R. 3290), the "Transparent Price Act (H.R. 3281)", the "Lower Costs, More Transparency Act (H.R. 5378)", "Educate Act (H.R. 7725)" and the "Continuing Appropriations and Extension Act, 2025 (H.R. 9747)".
Client expense: Not reported · Firm income: $33,750
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · third_quarter · Medicare/Medicaid
H.R. 1613 / S. 1038, the Drug Price Transparency in Medicaid Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 2880, the Protecting Patients Against PBM Abuses Act; H.R. 1770 / S. 2477, the Equitable Community Access to Pharmacist Services Act; S. 1491, the Pharmacy and Medically Underserved Areas Enhancement Act; H.R. 2816, the PBM Sunshine and Accountability Act; H.R. 3281, the Transparent PRICE Act; H.R. 3282, the Promoting Transparency and Healthy Competition in Medicare Act; H.R. 3561, the PATIENT Act; S. 1967, the Patients Before Middlemen (PBM) Act; S. 2129, the Ensuring Access to Lower-Cost Medicines for Seniors Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S. 2973, the Modernizing and Ensuring PBM Accountability Act; H.R. 5378, the Lower Costs, More Transparency Act; H.R.5385, the Medicare PBM Accountability Act; H.R. 5393, to amend title XVIII of the Social Security Act to ensure fair assessment of pharmacy performance and quality under Medicare part D, and for other purposes; H.R. 5400 / S. 2436, the NO PBMs Act; S.3430,the Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023; Request for Information for "Medicare Transaction Facilitator (MTF) for the Medicare Drug Price Negotiation Program in the Inflation Reduction Act" (IRA; P.L. 117-169); Comments for "Medicare Prescription Payment Plan: Draft Part Two Guidance on Select Topics, Implementation of Section 1860D-2 of the Social Security Act for 2025" (IRA, P.L. 117-169); Comments for Final Rule Document 2022-09375, "Medicare Program, Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs..." (87 FR 27704); Comments for "Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies" (CMS-2024-0006); Request for Information for Bipartisan 340B Senate Working Group SUSTAIN 340B Act Discussion Draft; H.R.4366, the Consolidated Appropriations Act, 2024 H.R.2882, the Further Consolidated Appropriations Act, 2024 Cybersecurity protocols and policies in health care system and the impact on claims processing and reimbursement; Comments to CMS on the implementation of Medicare Part D vaccine coverage under the Inflation Reduction Act (IRA; P.L. 117-169); Comments to CMMI on the Importance of Implementing Reasonable Reimbursement Guardrails for Pharmacies in the Medicare $2 Drug List Model based on the Executive Order on Lowering Prescription Drug Costs for Americans; Comments to HHS and CMS on 2024 NADAC Methodology Changes; Comment to CMS on "Medicare Drug Price Negotiation Program: Draft Guidance, Implementation of Sections 1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2027 and Manufacturer Effectuation of the Maximum Fair Price (MFP) in 2026 and 2027."; H.R. 9096, the Pharmacists Fight Back Act; Long Term Care at Home Pharmacy Services in Medicare; Regulating fair and common-sense contracting guardrails between Part D plans/PBMs, and pharmacies; Comments to CMS on Proposed Rule Re: Medicare and Medicaid Programs; CY 2025 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; Medicare Prescription Drug Inflation Rebate Program; and Medicare Overpayments [CMS-1807-P]; H.R.4758, the Accelerating Kids Access to Care Act; H.R. 8107, the Ensuring Access to Medicaid Buy-in Programs Act of 2024; Comments to CMS on Draft Guidance Re: Medicare Drug Price Negotiation Program: Draft Guidance, Implementation of Sections 1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2027 and Manufacturer Effectuation of the Maximum Fair Price (MFP) in 2026 and 2027;
Client expense: $380,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Small Business Administration (SBA), White House Office
2024 · third_quarter · Health Issues
Support S. 127 PBM Transparency Act; support S. 1001/H.R. 1843 Telehealth Expansion Act; support H.R. 3561 PATIENT Act (formerly H.R. 3281 Transparent Price Act); support S. 1339 PBM Reform Act; support H.R. 5378 Lower Costs, More Transparency Act.
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · second_quarter · Pharmacy
Issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, Protecting Patients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of 2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act; H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modernizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0); H.R.3285 - Fairness for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R.7535, Prescription Drug Supply Chain Pricing Transparency Act; H.R. 6986/S.3583, to address patent thickets; S. 2220, Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act); H.R. 8261, the Preserving Telehealth, Hospital, and Ambulance Access Act; Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future of 340B Act (SUSTAIN 340B Act); H.R. 8574, 340B Affording Care for Communities and Ensuring a Strong Safety-Net Act (340B ACCESS Act; S.150, the Affordable Prescription Drug for Patients Act; S. 148, the Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act (Stop STALLING Act); S. 142, the Preserve Access to Affordable Generics and Biosimilars Act.
Client expense: $2,200,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · second_quarter · Health Issues
Issues regarding childrens health care coverage and access to care under Medicaid, CHIP, the Exchanges, and private insurance Issues regarding the annual Notice of Benefit and Payment Parameters for the Exchanges and private insurance H.R. 2412 The Helping Kids Cope Act S.2372/HR. 4758 - Accelerating Kids Access to Care Act Issues regarding childrens and mothers health specifically continuous eligibility for children in Medicaid and CHIP, CHIP permanency Issues regarding childrens mental health and the national emergency in childrens mental health, including mental health parity, the mental health workforce and related access issues. Issue regarding Medicaid supplemental payments and directed payments Issues related to Health Information Technology, interoperability, information blocking, and cybersecurity Pediatric Access to Critical Healthcare (PATCH) Act, and issues regarding pediatric health care infrastructure and capacity Issues regarding the importance of Medicaid to children, including military and veteran families Issues regarding Medicaid support for providers caring for children on Medicaid, including DSH payments Issues regarding Children's Hospitals Graduate Medical Education (CHGME) program and funding Issues related to 340B Drug Pricing Program, prescription drug pricing, drug shortages, high-cost drugs/therapies and pharmaceutical supply chain, including H.R. 3290 Issues related to pediatric workforce, Medicare GME, the Pediatric Specialty Loan Repayment Program, and Title VII and VIII Issues regarding Organ Procurement and Transplantation Network S. 3029/H.R. 6085 PREEMIE Reauthorization Act Issues regarding the Medicaid unwinding Issues regarding surprise billing, bad debt, and price transparency in health care Issues regarding pediatric pandemic and disaster preparedness and response and emergency preparedness Issues regarding food security and nutrition Issues regarding drugs and medical device shortages and high costs Issues related to the regulation of laboratory developed tests Issues regarding prescribing of drugs via telehealth Issues related to mental health services in schools Issues related to pediatric cancer and the Moonshot Issues regarding Artificial Intelligence (AI) H.R. 1117, Advancing Safe Medications for Moms and Babies Act of 2023 H.R. 4189, CONNECT for Health Act H.R. 1110, KEEP Telehealth Options Act H.R. 5541, Temporary Reciprocity to Ensure Access to Treatment (TREAT) Act Issues regarding the Public Health Emergency Unwinding Issues involving Site Neutral payment legislation, including H.R. 3281 and H.R. 3561 S. 1884/H.R. 3713, Mental Health Services for Students Act H.R. 2389, The Resident Shortage Reduction Act S. 1774/H.R. 3761 the Assist Act H.R. 2665, Supporting Safety Net Hospitals Act H.R. 2584/S.2768, Safety form Violence for Healthcare employees (Save) Act H.R. 3046, Medical Student Education Authorization Act S. 2556, Improving CARE for Youth Act S. 2647/H.R. 5012, SHINE for Autumn Act of 2023 S. 923/H.R. 4933, Mental Health Professionals Workforce Shortage Loan Repayment Act of 2023 S. 2362/H.R. 3008, Drug Shortage Prevention Act of 2023 S. 1409, Kids Online Safety Act S. 1769/H.R. 3805, the Kickstarting Innovative Demonstrations Supporting (KIDS) Health Act. H.R. 5804, Mental Health Infrastructure Improvement Act H.R. 5976 /S. 3060 Youth Mental Health Research Act S. 3364, Kid PROOF Act of 2023 H.R. 6664 Innovation for Pediatric Drugs Act of 2023 H.R. 7808, the Early Action and Responsiveness Lifts Youth (EARLY) Minds Act H.R. 7153/S. 3679 Dr. Lorna Breen Health Care Provider Protection Reauthorization Act S. 3757 Congenital Heart Futures Reauthorization Act of 2024 H.R. 6960 Emergency Medical Services for Children Reauthorization Act of 2024 H.R. 3391 Gabriella Miller Kids First Research Act 2.0 H.R. 6963 Pediatric Cancer Drug Supply Act H.R. 3433/ S. 2897, Give Kids A Chance Act H.R. 7384, Creating Hope Reauthorization Act. H.R. 6664, Innovation in Pediatric Drugs Act S. 4298: Esthers Law Issues regarding oversight and implementation of EPSDT
Client expense: $1,550,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Labor, Dept of (DOL), Office of Management & Budget (OMB), SENATE
2024 · second_quarter · Health Issues
S. 3679, Dr. Lorna Breen Health Care Provider Protection Reauthorization Act H.R. 5378 the Lower Costs, More Transparency Act S.3548 - Health Care Prices Revealed and Information to Consumers Explained Transparency Act S.3430 - An original bill to amend titles XVIII and XIX of the Social Security Act to expand the mental health care workforce and services, reduce prescription drug costs, and extend certain expiring provisions under Medicare and Medicaid, and for other purposes. HR 3305 & S. 1606 Black Maternal Health Momnibus Act HR 4822 Health Care Price Transparency Act HR 3284 Providers and Payers COMPETE Act HR 2840 Bipartisan Primary Care and Health Workforce Act HR 4818 Treat and Reduce Obesity Act of 2023 S. 2333 Pandemic and All Hazards Preparedness and Response Act H.R. 4421 Preparing for All Hazards and Pathogens Reauthorization Act H.R. 3561, PATIENT Act of 2023 H.R. 3281, the Transparent PRICE Act H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information H.R. 2868 Association Health Plans Act H.R. 2813 Self-Insurance Protection Act H.R. 3799 CHOICE Arrangement Act H.R. 3432, Telemental Health Care Access Act H.R.824, Telehealth Benefit Expansion for Workers Act of 2023 H.R. 4189, S. 2016, CONNECT for Health Act S. 923, Better Mental Health Care for Americans Act H.R. 3120, Healthy Competition for Better Care Act H.R. 1843 Telehealth Expansion Act of 2023 Legislation and regulation related to health care delivery and health insurance coverage, mental health and substance use disorder care and coverage, the transition out of the COVID-19 pandemic and electronic health information/technology. S.954 - 118th Congress (2023-2024)A bill to provide for appropriate cost-sharing for insulin products covered under private health plans, and to establish a program to support health care providers and pharmacies in providing discounted insulin products to uninsured individuals. a
Client expense: $680,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2024 · second_quarter · Medicare/Medicaid
H.R. 1613 / S. 1038, the Drug Price Transparency in Medicaid Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 2880, the Protecting Patients Against PBM Abuses Act; H.R. 1770 / S. 2477, the Equitable Community Access to Pharmacist Services Act; S. 1491, the Pharmacy and Medically Underserved Areas Enhancement Act; H.R. 2816, the PBM Sunshine and Accountability Act; H.R. 3281, the Transparent PRICE Act; H.R. 3282, the Promoting Transparency and Healthy Competition in Medicare Act; H.R. 3561, the PATIENT Act; S. 1967, the Patients Before Middlemen (PBM) Act; S. 2129, the Ensuring Access to Lower-Cost Medicines for Seniors Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S. 2973, the Modernizing and Ensuring PBM Accountability Act; H.R. 5378, the Lower Costs, More Transparency Act; H.R.5385, the Medicare PBM Accountability Act; H.R. 5393, to amend title XVIII of the Social Security Act to ensure fair assessment of pharmacy performance and quality under Medicare part D, and for other purposes; H.R. 5400 / S. 2436, the NO PBMs Act; S.3430,the Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023; Request for Information for "Medicare Transaction Facilitator (MTF) for the Medicare Drug Price Negotiation Program in the Inflation Reduction Act" (IRA; P.L. 117-169); Comments for "Medicare Prescription Payment Plan: Draft Part Two Guidance on Select Topics, Implementation of Section 1860D-2 of the Social Security Act for 2025" (IRA, P.L. 117-169); Comments for Final Rule Document 2022-09375, "Medicare Program, Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs..." (87 FR 27704); Comments for "Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies" (CMS-2024-0006); Request for Information for Bipartisan 340B Senate Working Group SUSTAIN 340B Act Discussion Draft; H.R.4366, the Consolidated Appropriations Act, 2024 H.R.2882, the Further Consolidated Appropriations Act, 2024 Cybersecurity protocols and policies in health care system and the impact on claims processing and reimbursement; Comments to CMS on the implementation of Medicare Part D vaccine coverage under the Inflation Reduction Act (IRA; P.L. 117-169); Comments to CMMI on the Importance of Implementing Reasonable Reimbursement Guardrails for Pharmacies in the Medicare $2 Drug List Model based on the Executive Order on Lowering Prescription Drug Costs for Americans; Comments to HHS and CMS on 2024 NADAC Methodology Changes; Comment on "Medicare Drug Price Negotiation Program: Draft Guidance, Implementation of Sections 1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2027 and Manufacturer Effectuation of the Maximum Fair Price (MFP) in 2026 and 2027.";
Client expense: $340,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Small Business Administration (SBA), White House Office
2024 · second_quarter · Health Issues
Support for H.R.7327 - Protecting Front Line Multimission Hospitals Act of 2024. Sustainability of safety net health systems. Social determinants of health. Promoting coordinated care. Support of telehealth policies, including for audio-only telehealth services. 340B Protect Act, H.R.4390. H.R.3290, To amend Title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. H.R.1613, Drug Price Transparency in Medicaid Act of 2023. H.R.2665, Supporting Safety Net Hospitals Act. H.R.3281, Transparent PRICE Act. H.R.3561, Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023. Support for policies to enhance health care workforce programs. H.R.5378, Lower Costs, More Transparency Act. S.3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act. S.3450, Mental and Physical Health Care Comorbidities Act of 2023. Support for policies to enhance healthcare workforce programs.
Client expense: Not reported · Firm income: $40,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2024 · second_quarter · Health Issues
Issues related to drug pricing reform -Changes to Public law 117-1769 Inflation Reduction Act -Awareness of implications to patients and research and development of Public law 117-1769 Inflation Reduction Act S. 113 Prescription Pricing for the People Act of 2023 S.127 Pharmacy Benefit Manager Transparency Act HR 830/ S 1375 HELP Copays Act HR 485 Protecting Health Care for All Patients Act HR 5378 Lower Costs, More Transparency Act R 2534 PROTECT 340B Act of 2023 HR 3561 the PATIENT Act S. 1542/ hr 6283 DRUG Act S. 1967 PBM Act HR 3503 The NIH Clinical Trials Diversity Act Issues related to cardiovascular disease awareness and treatment Issues related to Federal Trade Commission FDA issues Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Biosimilars reimbursement issues, no specific bill Supply Chain Issues, no specific bill Issues related to 340B Issues related to pharmacy benefit managers Proposed rule: Medicaid Program; Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program HR 4818/ S. 2407 Treat and Reduce Obesity Act S. 2305 Biosimilar Red Tape Elimination Act S. 2129 Ensuring Access to Lower-Cost Medicines for Seniors Act Issues related to PAHPA reauthorization Modernizing and Ensuring PBM Accountability Act (Finance Committee) S. 652 SAFE Step Act S 2474/ HR 5376 Share the Savings with Seniors Act S 2456 Protecting Seniors from High Drug Costs Act HR4881 To amend title XVIII of the Social Security Act to limit cost sharing for drugs under the Medicare program HR 3281 Protecting Patients Against PBM Abuses Act HR 4822 Health Care Price Transparency Act of 2023 S 1339 Pharmacy Benefit Manager Reform Act HR 2679 Pharmacy Benefits Manager Accountability Act HR 4507 Transparency in Coverage Act of 2023 HR 1352 Increasing Access to Biosimilars Act of 2023 HR 2880 Protecting Patients Against PBM Abuses Act Issues pertaining to the implementation of PL 97-414 "Orphan Drug Act," all provisions. HR 5539 Orphan Cures Act HR 5547 Maintaining Investments in New Innovation Act S 3558 BIOSECURE Act HR 7174 Ensuring Pathways to Innovative Cures (EPIC Act) S Res 566 Cholesterol Education Month 2024 HR 7635 340B PATIENTS Act of 2024 H.R. 5391 / S. 2764 The Protecting Patient Access to Cancer and Complex Therapies Act . H.R.8574 - 340B Affording Care for Communities and Ensuring a Strong Safety-net Act . HR 5376 Share the Savings With Seniors Act . S 3430 Mental Health, Lower Cost Drugs and Extenders Package . BIOCOMPETE (no bill number)- Issues related to prohibiting the export of biotechnology to certain foreign entities
Client expense: $2,740,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2024 · second_quarter · Medicare/Medicaid
Issues related to drug pricing reform -Changes to Public law 117-1769 Inflation Reduction Act -Awareness of implications to patients and research and development of Public law 117-1769 Inflation Reduction Act S. 113 Prescription Pricing for the People Act of 2023 S.127 Pharmacy Benefit Manager Transparency Act HR 485 Protecting Health Care for All Patients Act HR 5378 Lower Costs, More Transparency Act HR 2534 PROTECT 340B act of 2023 HR 3561 the PATIENT act Issues related to cardiovascular disease awareness and treatment Issues related to ESRD Issues related to asthma and self-administered drug list Issues related to reimbursement for biologics/biosimilars Proposed rule: Medicaid Program; Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program HR 4818/ S2407 Treat and Reduce Obesity Act S2129 Ensuring Access to Lower-Cost Medicines for Seniors Act Issues related to PAHPA reauthorization Modernizing and Ensuring PBM Accountability Act (Finance Committee) S. 1542/ HR 6283 DRUG Act S652 SAFE Step Act HR 3281 Protecting Patients Against PBM Abuses Act HR 4822 Health Care Price Transparency Act of 2023 S 1339 Pharmacy Benefit Manager Reform Act HR 2679 Pharmacy Benefits Manager Accountability Act HR 4507 Transparency in Coverage Act of 2023 S 2474/HR 5376 Share the Savings with Seniors Act S 2456 Protecting Seniors from High Drug Costs Act HR4881 To amend title XVIII of the Social Security Act to limit cost sharing for drugs under the Medicare program HR 1352 Increasing Access to Biosimilars Act of 2023 HR 2880 Protecting Patients Against PBM Abuses Act HR 5547 Maintaining Investments in New Innovation Act HR 7174 Ensuring Pathways to Innovative Cures (EPIC Act) HR 7635 340B PATIENTS Act of 2024 H.R. 5391 / S. 2764 The Protecting Patient Access to Cancer and Complex Therapies Act . H.R.8574 - 340B Affording Care for Communities and Ensuring a Strong Safety-net Act . HR 5376 Share the Savings With Seniors Act . S 3430 Mental Health, Lower Cost Drugs and Extenders Package . HR 5539 Orphan Cures Act
Client expense: $2,740,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2024 · second_quarter · Medicare/Medicaid
Issues related to affordable prescription drugs; Issues related to telehealth authorities; Issues related to health care workforce and staffing; Medicaid Disproportionate Share Hospital payment adjustment program; Issues related to Medicaid coverage; Issues related to hospital reimbursement; 340B Program; Issues related to hospital price transparency; Issues related to Medicare payments; Issues related to Medicare Advantage payment and prior authorization; Future Advancement of Academic Nursing (FAAN) Act; Expanding Care in the Home Act; H.R. 1770, Equitable Access to Pharmacy Services Act; issues related to Program for All-Inclusive Care for the Elderly (PACE); issues related to improving coordination of care for dual eligibles; issues related to site neutral payments; H.R. 3281, the Transparent PRICE Act; issues related to prior authorization, unwarranted claim denials, and payment delays; the Biologics Price Competition and Innovation Act (BPCIA); H.R. 3561, the PATIENT Act; H.R. 6363, Further Continuing Appropriations and Other Extension Act; H.R. 5378, the Lower Costs, More Transparency Act; PL 118-42/H.R. 4366 - Consolidated Appropriations Act, 2024; PL 118-47/H.R. 2882 - Consolidated Appropriations Act, 2024; Issues related to mental and behavioral health; the limit on Medicare payment days for inpatient psychiatric care; the Institutions for Mental Disease exclusion; issues related to extending programs under the SUPPORT for Patients Communities Act.
Client expense: $300,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2024 · second_quarter · Health Issues
Sustainability of safety net health systems; social determinants of health; promoting coordinated care; support of telehealth policies; 340B Protect Act, H.R. 4390; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 3281, the Transparent PRICE Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2665, the Supporting Safety Net Hospitals Act; and H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023; H.R. 5378, the Lower Costs, More Transparency Act; S.3548, the Health Care Prices Revealed and Information to Consumers Explained Transparency Act; H.R.6363, the Further Continuing Appropriations and Other Extensions Act, 2024; H.R. 2872, Further Additional Continuing Appropriations and Other Extensions Act, 2024; H.R. 7463, Extension of Continuing Appropriations and Other Matters Act, 2024; H.R. 8247, the Uterine Fibroid Intervention and Gynecological Health Treatment Act of 2024; and H.R. 8574, the 340B Affording Care for Communities and Ensuring a Strong Safety-net Act.
Client expense: $130,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2024 · second_quarter · Automotive Industry
Motor Vehicle Safety. Infrastructure Investment. H.R.2670 - National Defense Authorization Act for Fiscal Year 2024. H.R.3281/S.2736 - Protection of Motorsports Act of 2021 or the RPM Act of 2021. H.R. 1 - Lower Energy Costs Act. Artificial intelligence. H.R.906 - REPAIR Act. H.R.815 - Making emergency supplemental appropriations for the fiscal year ending September 30, 2024, and for other purposes.
Client expense: $150,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Environmental Protection Agency (EPA), Federal Communications Commission (FCC), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Natl Institute of Standards & Technology (NIST), SENATE, State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, White House Office
2024 · second_quarter · Health Issues
Transparency (surprise medical bills; public posting of hospital charges) 340B Drug Pricing Program (H.R. 3290) Rural health care innovation (PA Rural Health Model) Public Health Emergency designation SAVE Act (H.R. 2584) Fairness for Rural Teaching Hospitals Act (H.R.2433) Public Service Loan Forgiveness program/physician federal loan forgiveness Healthcare Workforce Behavioral health PATIENT Act of 2023 (H.R.3561) Nurse Staffing Standards for Hospital Patient Safety and Quality Care Act (S.1113, H.R.2530) CHGME Youth mental health Electronic health records Pandemic and All-Hazards Preparedness Reauthorization Act Nursing and allied health education (NAHE) program Bipartisan Primary Care and Health Workforce Act (S.2840) Transparent PRICE Act (H.R.3281) Save Americas Rural Hospitals Act (H.R.833) Supporting Safety Net Hospitals Act (H.R.2665) Patient Access to Higher Quality Care Act (H.R.977/S.470) FEMA Covid-19 reimbursement Health Care Price Transparency Act (H.R.4822) Providers and Payers Compete Act (H.R.3284) Lower Costs, More Transparency Act (H.R.5378) Health Care Prices Revealed and Information to Consumers Explained Transparency Act (S.3548) Medical and Nurse Licensure Compact Health care consolidation
Client expense: $60,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · second_quarter · Health Issues
Q2 Lobbying Report (April 1-June 30) HCR Transparency (surprise medical bills; public posting of hospital charges) 340B Drug Pricing Program Resident Physician Shortage Act of 2023 (H.R. 2389) No Surprises Act regulations Food and Drug Amendments No Surprise Bills for New Moms Act (H.R. 3387) Securing the U.S. Organ Procurement and Transplantation Network Act (H.R. 2544) Promoting Access to Treatments and Increasing Extremely Needed Transparency Act (H.R. 3561) Medicaid VBPs for Patients (MVP) Act (H.R. 2666) Providers and Payers COMPETE Act (H.R. 3284) To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program (H.R. 3290) Transparent PRICE Act (H.R. 3281/H.R. 2691)) Resident Physician Shortage Reduction (S. 1302) Medical Student Education Authorization Act (H.R. 3046) Save Americas Rural Hospitals Act (H.R. 833) Chronic Care Management Improvement Act (H.R. 2829) Safety From Violence for Healthcare Employees Act (H.R. 2584) Supporting Safety Net Hospitals Act (H.R. 2665) Patient Access to Higher Quality Health Care Act (H.R. 977/S.470) FEMA re: COVID-19 related reimbursement Public Health Guidance Transparency and Accountability Act of 2023 (H.R. 4529) Public Health Emergency Congressional Review Act (H.R. 4381) CDC Leadership Accountability Act of 2023 (H.R. 3813) Preparing for All Hazards and Pathogens Reauthorization Act (H.R. 4421) Preparedness and Response Reauthorization Act (H.R. 4420) Childrens Hospital GME Support Reauthorization Act of 2023 (H.R. 3887) Health Care Price Transparency Act of 2023 (H.R. 4822) Providers and Payers COMPETE Act (H.R. 3284) Lower Costs, More Transparency Act (H.R. 5378 Transparency in Coverage Act (H.R. 4507) GOLD Card Act of 2023 (H.R. 4968) No Fees for EFTs Act (H.R.6487) Rural Health Care Facilities Revitalization Act (H.R. 5989) Dr. Lorna Breen Health Care Provider Protection Reauthorization Act (H.R. 7153) To amend title XVIII of the Social Security Act to establish a definition of essential health system in statute (H.R. 7397) Substance Use Disorder Workforce Act (H.R. 7050) 340B PATIENTS Act (H.R. 7635) The 340B Affording Care for Communities and Ensuring a Strong Safety-net (ACCESS) Act (H.R. 8574) Improving Seniors Access to Timely Care Act (H.R. 8702/S.4532) The Preserving Emergency Access in Key Sites (PEAKS) Act (H.R. 7931) Rural Health Care Facilities Revitalization Act (H.R. 5989) MMM Accelerated and Advance Payment Program repayment flexibility Graduate Medical Education (GME) funding Telehealth flexibilities and payment Annual Prospective Payment System Rules Organ acquisition payment policies Californias Medicaid Hospital Quality Assurance Fee Program BUD FY 2024 Appropriations bills Nursing and allied health workforce funding FY 2024 budget request Further Continuing Appropriations and Other Extensions Act (H.R. 6363) Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R. 5894) Tax Relief for American Families and Workers Act of 2024 (H.R. 7024) Extension of Continuing Appropriations and Other Matters Act, 2024 (H.R. 7463) Submitted Comments Regulatory Comment Letters SUBJECT: CMS-1808-P, Medicare and Medicaid Programs and the Childrens Health Insurance Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Policy Changes and Fiscal Year 2025 Rates; Quality Programs Requirements; and Other Policy Changes; Proposed Rule, Federal Register (Vol. 89, No. 86), May 2, 2024 SUBJECT: CMS-4207-NC, Medicare Program; Request for Information on Medicare Advantage Data, Federal Register (Vol. 89, No. 20), January 30, 2024 SUBJECT: CMS-1806-P, Medicare Program; FFY 2025 Inpatient Psychiatric Facilities Prospective Payment System - Rate Update, Proposed Rule, Federal Register (Vol. 89, No. 65), April 3, 2024 SUBJECT: CMS-1804-P, Medicare Program; Inpatient Rehabilitation Facility Prospective Payment System for FFY 2025 and Updates to the IRF Quality Reporting Program; Proposed Rule, Federal Register (Vol. 89, No. 62), March 29, 2024 SUBJECT: Docket No. ATR 102 - Request for Information on Consolidation in Health Care Markets SUBJECT: CMS-3367-P, Medicare Program; Strengthening Oversight of Accrediting Organizations (AOs) and Preventing AO Conflict of Interest, and Related Provisions, Proposed Rule, Federal Register (Vol 89, No 32), February 15, 2024 Legislative Comment Letters Rep. Ami Bera Request for Information Regarding the Current State of Artificial Intelligence (AI) in the Health Care Industry, April 30, 2024 Senate Request for Information Regarding Draft SUSTAIN 340B Act, April 1, 2024
Client expense: $420,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), SENATE, Social Security Administration (SSA)
2024 · second_quarter · Health Issues
Support S. 127 PBM Transparency Act; support S. 1001/H.R. 1843 Telehealth Expansion Act; support H.R. 3561 PATIENT Act (formerly H.R. 3281 Transparent Price Act); support S. 1339 PBM Reform Act; support H.R. 5378 Lower Costs, More Transparency Act.
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · second_quarter · Health Issues
Monitoring legislation that could impact access to hospital or physician care, particularly related to the Medicare and Medicaid programs and the 340B drug discount program. In addition, monitoring legislation that could impact health care workforce training or behavioral health services or medical research or related to the use of telehealth. Specific legislation includes: legislation related to outpatient departments and unique identification numbers (H.R. 3237)", The "Resident Physician Shortage Reduction Act (H.R. 2389/S.1302)", the "Patient Act (H.R. 3561)", legislation related to the 340B drug discount program (H.R. 3290), the "Transparent Price Act (H.R. 3281)", the "Bipartisan Primary Care and Workforce Act (S.2840)", the "Lower Costs, More Transparency Act (H.R. 5378)", and the "Educate Act (H.R. 7725)".
Client expense: Not reported · Firm income: $33,750
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · first_quarter · Health Issues
H.R.4366 - Consolidated Appropriations Act, 2024 H.R. 2882, the Further Consolidated Appropriations Act, 2024 H.R. 7463, the Extension of Continuing Appropriations and Other Matters Act, 2024 H.R. 6363 Further Continuing Appropriations and Other Extensions Act of 2024 H.R. 5378 the Lower Costs, More Transparency Act S.3548 - Health Care Prices Revealed and Information to Consumers Explained Transparency Act S.3430 - An original bill to amend titles XVIII and XIX of the Social Security Act to expand the mental health care workforce and services, reduce prescription drug costs, and extend certain expiring provisions under Medicare and Medicaid, and for other purposes. S.1378 - Connecting Our Medical Providers with Links to Expand Tailored and Effective Care HR 3305 & S. 1606 Black Maternal Health Momnibus Act HR 4822 Health Care Price Transparency Act HR 3284 Providers and Payers COMPETE Act HR 2840 Bipartisan Primary Care and Health Workforce Act HR 4818 Treat and Reduce Obesity Act of 2023 S. 2333 Pandemic and All Hazards Preparedness and Response Act H.R. 4421 Preparing for All Hazards and Pathogens Reauthorization Act H.R. 3561, PATIENT Act of 2023 H.R. 3281, the Transparent PRICE Act H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information H.R. 2868 Association Health Plans Act H.R. 2813 Self-Insurance Protection Act H.R. 3799 CHOICE Arrangement Act H.R. 3432, Telemental Health Care Access Act H.R.824, Telehealth Benefit Expansion for Workers Act of 2023 H.R. 4189, S. 2016, CONNECT for Health Act S. 923, Better Mental Health Care for Americans Act H.R. 3120, Healthy Competition for Better Care Act H.R. 1843 Telehealth Expansion Act of 2023 Legislation and regulation related to health care delivery and health insurance coverage, mental health and substance use disorder care and coverage, the transition out of the COVID-19 pandemic and electronic health information/technology. S.954 - 118th Congress (2023-2024)A bill to provide for appropriate cost-sharing for insulin products covered under private health plans, and to establish a program to support health care providers and pharmacies in providing discounted insulin products to uninsured individuals. a
Client expense: $140,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2024 · first_quarter · Health Issues
Transparency (surprise medical bills; public posting of hospital charges) 340B Drug Pricing Program (H.R. 3290) Rural health care innovation (PA Rural Health Model) Public Health Emergency designation SAVE Act (H.R. 2584) Fairness for Rural Teaching Hospitals Act (H.R.2433) Public Service Loan Forgiveness program/physician federal loan forgiveness Healthcare Workforce Behavioral health PATIENT Act of 2023 (H.R.3561) Nurse Staffing Standards for Hospital Patient Safety and Quality Care Act (S.1113, H.R.2530) CHGME Youth mental health Electronic health records Pandemic and All-Hazards Preparedness Reauthorization Act Nursing and allied health education (NAHE) program Bipartisan Primary Care and Health Workforce Act (S.2840) Transparent PRICE Act (H.R.3281) Save Americas Rural Hospitals Act (H.R.833) Supporting Safety Net Hospitals Act (H.R.2665) Patient Access to Higher Quality Care Act (H.R.977/S.470) FEMA Covid-19 reimbursement Health Care Price Transparency Act (H.R.4822) Providers and Payers Compete Act (H.R.3284) Lower Costs, More Transparency Act (H.R.5378)
Client expense: $90,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · first_quarter · Health Issues
Transparency (surprise medical bills; public posting of hospital charges) 340B Drug Pricing Program (H.R. 3290) Rural health care innovation (PA Rural Health Model) Public Health Emergency designation SAVE Act (H.R. 2584) Fairness for Rural Teaching Hospitals Act (H.R.2433) Public Service Loan Forgiveness program/physician federal loan forgiveness Healthcare Workforce Behavioral health PATIENT Act of 2023 (H.R.3561) Nurse Staffing Standards for Hospital Patient Safety and Quality Care Act (S.1113, H.R.2530) CHGME Youth mental health Electronic health records Pandemic and All-Hazards Preparedness Reauthorization Act Nursing and allied health education (NAHE) program Bipartisan Primary Care and Health Workforce Act (S.2840) Transparent PRICE Act (H.R.3281) Save Americas Rural Hospitals Act (H.R.833) Supporting Safety Net Hospitals Act (H.R.2665) Patient Access to Higher Quality Care Act (H.R.977/S.470) FEMA Covid-19 reimbursement Health Care Price Transparency Act (H.R.4822) Providers and Payers Compete Act (H.R.3284) Lower Costs, More Transparency Act (H.R.5378)
Client expense: $90,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · first_quarter · Health Issues
Issues related to prescription drug coverage and pharmacy benefits Issues related to the prescription drug marketplace, patents, and competition Regulatory and proposed legislative changes to Medicare Part D and Medicaid prescription drug benefits S.113 - Prescription Pricing for the People Act S.127 - Pharmacy Benefit Manager Transparency Act S.142 - Preserve Access to Affordable Generics and Biosimilars Act S.148 - Stop STALLING Act S.150 - Affordable Prescriptions for Patients Act S.652 - Safe Step Act S.655 - Chronic Disease Management Act S.727 - Insulin for All Act S.775 - Increasing Transparency in Generic Drug Applications Act S.954 - Affordable Insulin Now Act S.1038 - Drug Price Transparency in Medicaid Act S.1067 - Ensuring Timely Access to Generics Act S.1114 - Expanding Access to Low-Cost Generics Act S.1120 - Improved Access to Affordable Medications Act S.1128 - Ensuring Access to Generic Medications Act S.1130 - Health Care PRICE Transparency Act S.1131 - Drug Price Transparency Act S.1217 - Ending the Prescription Drug Kickback Act S.1218 - Fair Prescription Drug Prices for Americans Act S.1269 - INSULIN Act S.1339 - Pharmacy Benefit Manager Reform Act S.1375 - HELP Copays Act S.1497 - Emergency Access to Insulin Act S.1491 - Pharmacy and Medically Underserved Areas Enhancement Act S.1542 - Delinking Revenue from Unfair Gouging (DRUG) Act S.1543 - A bill to require regulations concerning the disclosure of direct and indirect compensation from entities providing pharmacy benefit management services or third party administration services S.1967 - Patients Before Middlemen (PBM) Act S.2052 - Protect Patient Access to Pharmacies Act S.2129 - Ensuring Access to Lower-Cost Medicines for Seniors Act S.2254 - Medicare PBM Accountability Act S.2405 - Strengthening Pharmacy Access for Seniors Act S.2406 - PBM Oversight Act S.2408 - IMPROVE Part D Regulations Act S.2436 - Neighborhood Options for Patients Buying Medicines (NO PBM) Act S.2456 - Protecting Seniors from High Drug Costs Act S.2474 - Share the Savings with Seniors Act S.2477 - Equitable Community Access to Pharmacist Services Act S.2493 - PBM Reporting Transparency Act S.2666 - EPCS 2.0 Act S.2840 - Bipartisan Primary Care and Health Workforce Act (Bruan Amendment #3 - Price Transparency Requirements) S.2939 - Pharmacy Access Oversight and Reporting Act S.2973 - Modernizing and Ensuring PBM Accountability Act S.3430 - Better Mental Health Care, Lower-Cost Drugs, and Extenders Act H.R.830 - HELP Copays Act H.R.1352 - Increasing Access to Biosimilars Act H.R.1488 - Affordable Insulin Now Act H.R.1587 - Making Insulin Affordable for All Children Act H.R.1613 - Drug Price Transparency in Medicaid Act H.R.1770 - Equitable Community Access to Pharmacists Act H.R.1790 - Biologics Competition Act H.R.2630 - Safe Step Act H.R.2666 - Medicaid VBPs for Patients (MVP) Act H.R.2670 - PBM Accountability Act H.R.2691 - Transparent PRICE Act H.R.2880 - Protecting Patients Against PBM Abuses Act H.R.3030 - Stop the Overuse of Petitions and Get Affordable Medicines to Enter Soon (STOP GAMES) Act H.R.3134 - Emergency Access to Insulin Act H.R.3262 - to amend title XI of the Social Security Act to increase transparency of certain health-related ownership information H.R.3281 - Transparent PRICE Act H.R.3282 - Promoting Transparency and Health Competition in Medicare Act H.R.3285 - Fairness for Patient Medications H.R.3561- Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act H.R.3800 - Chronic Disease Flexible Coverage Act H.R.4011 - Timely Access to Clinical Treatment Act H.R.4507 - Transparency in Coverage Act H.R.4508 - Hidden Fee Disclosure Act H.R.4509 - Transparency in Billing Act H.R.4527 - Health Data Act H.R.4712 - Patient Right to Shop Act H.R.4822 - Health Care Price Transparency Act H.R.4846 - To amend the Internal Revenue Code of 1986, title XXVII of the Public Health Service Act, and the Employee Retirement Income Security Act of 1974 to provide for oversight of pharmacy benefit manager services H.R.4881 - To amend title XVIII of the Social Security Act to limit cost sharing for drugs under the Medicare program H.R.4883 - Medicare Common Ownership Transparency Act H.R.5372 - Expanding Seniors Access to Lower Cost Medicines Act H.R.5376 - Share the Savings with Seniors Act H.R.5378 - Lower Costs More Transparency Act H.R.5384 - Advancing Enrollment and Reducing Drug Costs Act H.R.5385 - Medicare PBM Accountability Act H.R.5386 - Cutting Copays Act H.R.5393 -Transparency and Fairness for Pharmacies Act H.R.5400 - Neighborhood Options for Patients Buying Medicines (NO PBM) Act H.R.5461 - Ensuring Access to Lower-Cost Medicines for Seniors Act Implementation of the Inflation Reduction Act of 2022, P.L. 169- Provisions on Medicare Part D modernization and drug price negotiation
Client expense: $4,803,802 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE